					(Based on PTO 08-08 version)	
0.4	stitute for form 1449/PTO			Complete if Known		
Substitute for form 1449/PTO				Application Number	09/847,945	
11	NFORMATION	l DI	SCLOSURE	Filing Date	May 2, 2001	
	TATEMENT E			First Named Inventor	Neil P. DESAI	
_				Art Unit	1611	
	(Use as many sh	ets a:	necessary)	Examiner Name	L. Channavajjala	
Sheet	1	of	2	Attorney Docket Number	638772000127	

U.S. PATENT DOCUMENTS							
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
	1.	US-2009/0304805-A1	12-10-2009	Desai et al.	3		
	2.	US-2010/0035800-A1	02-11-2010	Desai et al.			
	3.	US-2010/0112077-A1	05-06-2010	Desai et al.			
	4.	US-2010/0183728-A1	07-22-2010	Desai et al.			
	5.	US-2010/0166869-A1	07-01-2010	Desai et al.			
	6.	US-2010/0215751-A1	08-26-2010	Desai et al.			
	7.	US-6,146,663-A	11-14-2000	Bissery et al.			
	8.	US-6,239,124-B1	05-29-2001	Zenke et al.			
	9.	US-6,268,390-B1	07-31-2001	Kunz			
	10.	US-7,238,369-B2	07-03-2007	McDonald et al.			

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ² -Number ⁴ -Kind Code ⁵ (# known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶		
	11.	WO-87/04592-A1	08-13-1987	Liposome Technology, Inc.		П		
	12.	WO-96/25176-A1	08-22-1996	NeoRx Corporation		П		
	13.	WO 96/41236-A1	12-19-1996	The Regents of the University of California		П		
	14.	WO-97/33552-A1	09-18-1997	Wallace Technologies, Inc.		П		
	15.	WO-97/45105-A1	12-04-1997	Angiotech Pharmaceuticals, Inc.				

Examiner	Date	
Signature	Considered	

EXAMASE I related if information considered, whether or not classins in conformance with IMPER 900. Date fire through classins if an is conformance and not considered include surpress that one processing in a special of special special special special conformation in the conformation of the processing in the conformation of the processing in the conformation of the processing in the

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the Item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where cublished.				
	16.	BOLLAG, D.M. et al. (June 1, 1995). "Epothilones, a New Class of Microtubule-stabilizing Agents with Taxol-like Mechniasms of Action," Cancer Res. 55:2325-2333.	Τ			
	17.	DRACHMAN, D. E. et al. (December 2000). "Neointimal Thickening After Stent Delivery of Pacilitaxel: Change in Composition and Arrest of Growth over Six Months," J. Am. Coll. Cardiol. 36(7):2325-2332.				

	(Based on PTO 08-08 versio						
	astitute for form 1449/PTO			Complete if Known			
Sui	ostitute for form 1449/FTO			Application Number	09/847,945		
l m	NFORMATION	1 DI	SCLOSURE	Filing Date	May 2, 2001		
	TATEMENT			First Named Inventor	Neil P. DESAI		
~		• • •		Art Unit	1611		
	(Use as many sheets as necessary)			Examiner Name	L. Channavajjala		
Sheet	2	of	2	Attorney Docket Number	638772000127		

18.	MOSELEY, M.E. et al. (October 1991). "Microbubbles: A Novel MR Susceptibility Contrast Agent," 10th Annual Meeting of Society of Magnetic Resonance in Medicine, San Francisco, CA. one page.	
19.	NERI, R. O. et al. (June 1975). "Biological Aspects of Antiandrogens," J. Steroid Biochem. 6(6):815-819.	
20.	RON, N. et al. (April 2008). "Comparison of Physicochemical Characteristics and Stability of Three Novel Formulations of Pacilitaxel: Abraxane, Nanoxel, and Genexol PM," Abstract No. 5622, presented at 99" AACR Annual Meeting, San Diego, CA, April 12-16, 2008, located at <a 108="" href="http://www.aacrmeetingabstracts.org/cgi/content/meeting_abstract/2008/1_Annual_Meeting/5622" maxtohow-a-bittes="" resultformat-i="" sauthor1="ron-andoroxactitile-and-Sandoro</td"><td></td>	
21.	VERRECCHIA, T. et al. (September 1995). "Non-Stealth (Poly (Lactic Acid/Albumin)) and Stealth (Poly (Lactic Acid-Polyethylene Glycol)) Nanoparticles as Injectable Drug Carriers," J. Controlled Release 36:49-51.	
22.	KARANIAN, J. W. et al. (October 2010). "Efficiency of Drug Delivery to the Coronary Arteries in Swine is Dependent on the Route of Administration: Assessment of Luminal, Intimal, and Adventitial Coronary Artery and Venous Delivery Methods," J. Vasc. Interv. Radiol. 21:1555- 1564.	
23.	MARGOLIS, J. et al. (April 2007). "Systemic Nanoparticle Paclitaxel (nab-Paclitaxel) for In- Stent Restenosis I (SNAPIST-I): A First-in-Human Safety and Dose-Finding Study," Clin. Cardiol. 30:165-170.	
24.	U.S. Patent Application No. 12/713,092 filed on February 25, 2010, for Desai et al. (copy not attached).	
25.	U.S. Patent Application No.12/761,292 filed on April 15, 2010 for Desai et al. (copy not attached).	
26.	U.S. Patent Application No. 12/818,099 filed on June 17, 2010, for De et al. (copy not attached).	
27.	U.S. Patent Application No.12/824,014 filed on June 25, 2010 for Desai et al. (copy not attached).	
28.	U.S. Patent Application No. 12/832,876 filed on July 8, 2010, for Desai et al. (copy not attached).	
29.	U.S. Patent Application No.12/874,965 filed on September 2, 2010 for De et al. (copy not attached).	
30.	U.S. Patent Application No. 12/690,693, filed October 22, 1010, for Desai et al. (copy not attached).	

Examiner /Lakshmi Channavajjala/	Date Considered	03/10/2011
----------------------------------	--------------------	------------

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /L.C./

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.